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Background: Early, accurate diagnosis of mild traumatic brain injury (mTBI)
can improve clinical outcomes for patients, but mTBI remains difficult to
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diagnose because of reliance on subjective symptom reports. An objective
biomarker could increase diagnostic accuracy and improve clinical outcomes.
The aim of this study was to assess the ability of salivary noncoding RNA
(ncRNA) to serve as a diagnostic adjunct to current clinical tools. We hypoth-
esized that saliva ncRNA levels would demonstrate comparable accuracy for
identifyingmTBI asmeasures of symptom burden, neurocognition, and balance.
Methods: This case-control study involved 538 individuals. Participants
included 251 individuals with mTBI, enrolled ≤14 days postinjury, from 11 clini-
cal sites. Saliva samples (n= 679) were collected at five time points (≤3, 4-7, 8-14,
15-30, and 31-60 days post-mTBI). Levels of ncRNAs (microRNAs, small nucleo-
lar RNAs, and piwi-interacting RNAs) were quantified within each sample using
RNA sequencing. The first sample from each mTBI participant was compared to
saliva samples from 287 controls. Samples were divided into testing (n = 430;
mTBI = 201 and control = 239) and training sets (n = 108; mTBI = 50 and con-
trol = 58). The test set was used to identify ncRNA diagnostic candidates and
create a diagnostic model. Model accuracy was assessed in the naïve test set.
Results: A model utilizing seven ncRNA ratios, along with participant age and
chronic headache status, differentiated mTBI and control participants with a
cross-validated area under the curve (AUC) of .857 in the training set (95% CI,
.816-.903) and .823 in the naïve test set. In a subset of participants (n = 321;
mTBI = 176 and control = 145) assessed for symptom burden (Post-Concussion
Symptom Scale), as well as neurocognition and balance (ClearEdge System),
these clinical measures yielded cross-validated AUC of .835 (95% CI, .782-.880)
and .853 (95% CI, .803-.899), respectively. A model employing symptom bur-
den and four neurocognitive measures identified mTBI participants with sim-
ilar AUC (.888; CI, .845-.925) as symptom burden and four ncRNAs (.932; 95% CI,
.890-.965).
Conclusion: Salivary ncRNA levels represent a noninvasive, biologic measure
that can aid objective, accurate diagnosis of mTBI.
KEYWORDS
balance, biomarker, concussion, diagnosis, neurocognition, RNA, saliva, traumatic brain injury
1 INTRODUCTION
Mild traumatic brain injury (mTBI) is characterized
by brief confusion, loss of consciousness, posttraumatic
amnesia, and/or other transient neurological abnormali-
ties (eg, seizure), with a Glasgow Coma Scale score of 13-15
after 30 min postinjury or later.1 Nearly 3 million mTBIs
occur in the United States each year, and the majority
occur in adolescents and young adults.2–4 The prevalence
of mTBI in adolescents is on the rise, resulting in increas-
ing economic and healthcare system burden.5,6
mTBI is associated with significant morbidity, including
headaches, fatigue, and difficulties with concentration.2,7
mTBI is also associated with missed school or work, and
increased healthcare utilization.8 mTBI can have a wide
range of effects on physical, cognitive, and psycholog-
ical function, negatively impacting cognitive abilities,
academic performance, behavior, social interaction, and
employment.9–11 It can be difficult to identify the physical
and neurocognitive effects of mTBI, as some effects may
be attributed to other causes such as anxiety, depres-
sion, attention deficit hyperactivity disorder (ADHD),
exercise-related fatigue, or chronic headache disorder.
Because of this, physical and neurocognitive measures
have limited specificity and utility for diagnostic purposes
when administered alone.12 As such, identifying reliable
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objective biomarkers is necessary to effectively screen,
diagnose, and treat mTBI.
Another obstacle when screening formTBI is that symp-
toms and deficits often have delayed emergence.10 This
temporal pattern can be attributed to the natural progres-
sion in pathophysiologic changes, underdiagnosis, and/or
underreporting.12,13 As early diagnosis and intervention
can minimize latent adverse events (such as persistent
symptoms) and improve one’s quality of life, the ability to
quickly and accurately diagnosemTBI is critical to improv-
ing outcomes.5,13 However, studies show that mTBI is both
underdiagnosed and underreported.14,15
The 2018 guidelines on the diagnosis of mTBI from the
Centers for Disease Control and Prevention (CDC) advise
healthcare professionals to use age-appropriate, validated
symptom rating scales as a component of mTBI evalua-
tion (moderate, level B evidence), which can be accompa-
nied by computerized cognitive testing (moderate, level C
evidence).16 The guidelines specifically state that health-
care professionals should not use biomarkers outside of
a research setting (high, level R evidence), and the util-
ity of balance testing for mTBI diagnosis is not discussed.
Unfortunately, individuals seeking to expedite or delay
return-to-activities may manipulate cognitive measures
by “sandbagging” baseline tests, or exaggerate postinjury
symptom reports.17–19 In addition, the signs and symptoms
of mTBI can be subtle and easily missed in acute care
settings.14 To add to that challenge, many acute care and
emergency medicine providers report insufficient train-
ing to effectively diagnose and manage mTBI.20 Thus, a
reliable and objective mTBI diagnosis remains a critical
unmet need.
Anumber of alternative technologies for traumatic brain
injury (TBI) diagnosis have been proposed, including neu-
roimaging, electrophysiology, and blood biomarkers.21,22
Though these approaches have shown promise, they also
carry limitations that may impede clinical adoption.23 For
example, neuroimaging and electrophysiology technolo-
gies require expensive, nonportable equipment and spe-
cialist interpretation. Changes in blood-based proteins and
lipids following TBI demonstrate utility for determining
risk of intracranial bleeding and the utility of computed
tomography in adults.24 Recent advances in blood-based
biomarkers suggest they may soon provide clinical util-
ity for mTBI diagnosis.25–27 Yet, most mTBIs do not result
in intracranial bleeding. Further, protein biomarkers are
typically present at low concentrations (fM to pM), are
susceptible to degradation, and may have difficulty cross-
ing the blood-brain barrier in cases of mild injury.28–30
Further, athletic trainers who lack venipuncture training
cannot employ blood-based biomarkers field-side, where
over a third of mTBIs in adolescents and young adults
occur.3,10
Micro-ribonucleic acids (miRNAs) are a class of small,
noncoding RNAs (ncRNAs) that regulate protein tran-
scription through sequence-specific binding and degra-
dation of messenger RNA. Like other ncRNAs, includ-
ing small nucleolar RNAs (snoRNAs) and piwi-interacting
RNAs (piRNAs), miRNAs play an important role in brain
development.31 They have also been implicated in both
severe and mild forms of TBI.32,33 Neurons can package
ncRNAs within protective vesicles, allowing them to tra-
verse the extracellular space, dock at distant cells, and
influence gene expression.34 Thus, measurement of sali-
vary ncRNAs arising from the five cranial nerves in the
oropharynx may provide a noninvasive molecular window
into the physiology of mTBI.35,36 Previously, we showed
that miRNA levels in cerebrospinal fluid are mirrored in
the saliva of pediatric patients with mTBI.37 In a follow-
up study of 52 children with mTBI, saliva miRNA levels
accurately predicted duration of symptoms.38 Finally, we
showed that miRNA levels change within hours of mTBI,
and this response occurs in saliva before serum.39
To date, the diagnostic potential of salivary ncRNAs
has not been assessed in a large mTBI cohort with ade-
quate controls (ie, individuals with orthopedic injury [OI],
chronic headache, recent exercise, and neuropsychologi-
cal comorbidities). Further, the diagnostic accuracy of ncR-
NAs relative to current standard-of-care assessments has
not been tested. We hypothesized that measurement of
salivary ncRNAs would demonstrate comparable accuracy
for discerning mTBI in children and young adults, relative
to symptom burden, neurocognitive assessment, or bal-
ance measures. We also posited that a composite assess-
ment, combining saliva ncRNAmeasureswith other objec-
tive tools and subjective symptom reports, would increase
diagnostic accuracy. These hypotheses were tested in a
multisite, case-control study, involving 538 children and
young adults (251 with mTBI and 287 controls).
2 MATERIALS ANDMETHODS
Ethical approval for this study was provided through a
central institutional review board (Western IRB 1271583).
Institutional approval was also provided by independent
institutional review boards at the Penn State College of
Medicine (STUDY00003729), SUNY Upstate Medical Uni-
versity (1070727), Marist College (#S18-033), SUNY Buffalo
(study #00004347), Vanderbilt University Medical Center
(#181814), and Department of the Army, Regional Health
Command-Atlantic (#1510001-1). Written, informed con-
sent was obtained for all participants. Written assent
was provided by participants under 18 years of age.
The study was registered in the clinicaltrials.gov registry
(NCT02901821).
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2.1 Participants
This prospective multicenter, case-control study included
a convenience sample of 538 individuals, ages 5-66 years.
There were 251 individuals with a clinical diagnosis of
mTBI, defined by the 2016 Concussion in Sport Group
criteria as rapid-onset, short-lived, spontaneously resolv-
ing impairment in neurologic function, typically reflected
by functional disturbance rather than structural injury,
and characterized by a range of clinical symptoms (eg,
headache, dizziness, confusion, and amnesia) that may or
may not involve loss of consciousness.40 This broad defini-
tion of mTBI was chosen to include “mild” cases that did
not result in loss of consciousness, and potentially improve
the sensitivity of a resulting ncRNA diagnostic algorithm
in future investigations. The mTBI group included indi-
viduals with sport-related and nonsport mechanisms of
injury, enrolled fromemergency departments (EDs), sports
medicine clinics, urgent care centers, concussion specialty
clinics, and outpatient primary care clinics at initial clin-
ical presentation (within 14 days of injury). Following
enrollment, saliva and survey data were collected from
mTBI participants across five time points: <72 h (n = 129),
4-7 days (n= 120), 8-14 days (n= 190), 15-30 days (n= 105),
and 31-60 days postinjury (n = 135). The first sample from
each participant was used to generate the diagnostic algo-
rithm, whereas longitudinal samples were used only to
explore the physiologic characteristics of ncRNA candi-
dates postinjury (see Section 2.8, below).
The mTBI group was compared to a control group of 287
individuals with absence of mTBI in the previous 12 weeks
and clinical resolution of any previous mTBI. The control
group was enrolled from outpatient primary care clinics,
emergency departments, outpatient specialty care clinics,
and sports medicine clinics. To provide comparable rates
of OI, recent exercise (within 60min of sample collection),
and neuropsychological conditions (eg, depression and
anxiety) between control andmTBI groups, 25 control par-
ticipants were excluded from downstream analysis (Figure
S1). OI was defined as an upper/lower extremity sprain,
contusion, or fracture within 14 days of enrollment. Recent
exercisewas defined as≥30min ofmild/moderate physical
activity on the day of enrollment. A subset of control par-
ticipants with recent exercise (25/38) included collegiate
football athletes, for whom head impacts were recorded.
Research staff directly observed and recorded helmet-to-
ground, helmet-to-helmet, and helmet-to-body impacts for
each player during a full-contact practice immediately
prior to saliva collection. None of the football athletes were
diagnosedwithmTBI by athletic training staff in the course
of the practice.
All participants were enrolled from April 2017 through
February 2020 at 11 institutions: Adena Health System
(Chillicothe, OH; n = 37), Bridgewater College (Bridge-
water, VA; n = 20), Colgate University (Hamilton, NY;
n = 108), the United States Army (Fort Benning, GA;
n = 15), Marist College (Poughkeepsie, NY; n = 25), Penn
StateCollege ofMedicine (Hershey, PA; n= 224),NewYork
Institute of Technology (Old Westbury, NY; n = 36), State
University of New York (SUNY) at Buffalo Jacobs School
of Medicine (Buffalo, NY; n = 11), SUNY Upstate Medi-
cal University (Syracuse, NY; n = 38), Temple University
(Philadelphia, PA; n = 7), and Vanderbilt University Med-
ical Center (Nashville, TN; n = 17).
Exclusion criteria for all participants were primary lan-
guage other than English, pregnancy, active periodontal
disease, neurologic disorder (eg, epilepsy, multiple scle-
rosis, and hydrocephalus), drug or alcohol dependency,
current upper respiratory infection, legally appointed
guardian, or inability to provide consent/assent due to
intellectual disability. Participants were excluded from
the mTBI group for Glasgow Coma Score (GCS) ≤12 at
the time of initial injury, penetrating head injury, symp-
toms attributable to underlying psychological disorder (eg,
depression, anxiety, and posttraumatic stress disorder),
overnight hospitalization for current mTBI, presentation
for clinical care >14 days after the initial injury, skull frac-
ture, or findings of intracranial bleed on CT orMRI (if per-
formed). The proportion of participants who underwent
intracranial imaging was not recorded, but anecdotally,
the majority of mTBI participants had no imaging per-
formed. Participants were excluded from the control group
for ongoing rheumatologic or neoplastic condition, mTBI
in the previous 90 days, or persistence of symptoms from a
previous mTBI.
Participants were divided into a training set (80% of sam-
ples; n = 430 [mTBI = 201 and controls = 229]) used for
ncRNA exploration and creation of predictive algorithms,
and a naïve testing set (20% of samples; n= 108 [mTBI= 50
and controls = 58]) used only to validate the accuracy of
predictive algorithms. Samples were assigned randomly
to training and testing sets to ensure equal representa-
tion of age, sex, mTBI status, and symptom severity across
cohorts. Only one sample from each participant was used.
For mTBI participants, the first sample collected postin-
jury was employed.
2.2 Demographic and medical data
collection
Participant characteristics were collected via survey,
administered by research staff in the clinical care setting.
For children ≤12 years of age, parents assisted with sur-
vey completion. When possible, survey responses were
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confirmed through reviewof the electronicmedical record.
For all participants, the following medical and demo-
graphic characteristics were collected: age (years), sex
(male/female), ethnicity (White, Black or African Amer-
ican, Asian, Hispanic or Latino, American Indian or
Alaskan Native, and Native Hawaiian or Pacific Islander),
weight (kg), height (cm), body mass index (kg/m2),
dietary restrictions (presence/absence), and chronic med-
ical issues (presence/absence of ADHD, anxiety, depres-
sion, and chronic headache disorder). All participants
reported presence/absence of any previous TBI, time since
most recent TBI (days), and number of previous TBIs. Par-
ticipants in the mTBI group reported presence/absence of
loss of consciousness, and antero- or retro-grade memory
loss associated with recentmTBI. All participants reported
presence/absence of current OI.
2.3 Symptom assessment
For a subset of all participants (n = 387; mTBI = 208
and control = 179), 22 symptoms were self-reported on a
7-point Likert scale using the Post-Concussion Symptom
Scale (PCSS).41 Total symptom severity (sum of all Lik-
ert scores) and total symptom burden (sum of all symp-
toms >0) were calculated for each participant. Presence
or absence of symptoms >3 weeks after initial injury was
assessed for mTBI participants through self-report on the
PCSS, or through electronic medical record review (where
available).
2.4 Balance assessment
Balance was also assessed for a portion of participants
(n= 321; mTBI= 176 and control= 145) using the validated
ClearEdge system42,43 (Quadrant Biosciences Inc, Syra-
cuse, NY), as we have previously reported.39 ClearEdge
uses an inertial sensor (worn at the L4 vertebral level)
to measure body sway in three dimensions during eight
different stances: two legs eyes open (TLEO), tandem
stance eyes open (TSEO), two legs eyes closed (TLEC),
tandem stance eyes closed (TSEC), two legs eyes open on
a foam pad (TLEOFP), two legs eyes closed on a foam
pad (TLECFP), tandem stance eyes open on a foam pad
(TSEOFP), and tandem stance eyes closed on a foam pad
(TSECFP). The eight balance tests were scored in terms of
power spectral density of acceleration, scaled from 0 (poor
balance) to 100 (superior balance). There were 21 partici-
pants who were unable to complete balance testing due to
OI, or extreme postural instability that posed an increased
risk for falling.
2.5 Neurocognitive assessment
Computerized neurocognitive assessment was performed
in the same subset of participants (n = 321) using the fol-
lowing tests: simple reaction time (SRT1) in which the par-
ticipant recognizes the presence of an object on the screen
and taps it, procedural reaction time (PRT) in which the
participant recognizes one of four numbers and taps one
of two buttons, go/no-go (GNG) in which the participant
recognizes a green or gray object and only taps in response
to a gray, and a repeat of the simple reaction time test
(SRT2). This battery of tests is part of the Defense Auto-
mated Neurobehavioral Assessment (DANA).44,45 Though
a more extensive neurocognitive battery may demonstrate
improved detection of mTBI, these four tests were selected
to reduce participant dropout rates, and promote general-
izability within busy clinical settings. The four cognitive
tests were scored for speed and accuracy using a mean
throughput measure of mental efficiency, calculated as the
meannumber of correct responses perminute for each test.
Mean-throughput is not a scaled score and is test depen-
dent, with higher scores reflecting better performance (eg,
faster reaction time). All individual scores were objectively
calculated with computerized software.
2.6 Salivary ncRNA assessment
Saliva was collected from all participants (n = 538) in
a nonfasting state, following a tap water rinse. Highly
absorbent OraCollect Swabs (DNA Genotek, Ottawa
Canada) were applied under the tongue and near the
parotid glands bilaterally for 10-15 s. Swabs were sub-
merged in nucleic acid stabilizing solution and stored at
room temperature, prior to shipping via prioritymail to the
Molecular Analysis Core Facility at SUNY Upstate Medi-
cal University. RNA was isolated from each saliva sample
using the miRNeasy Kit (Qiagen, Inc, Germantown,
MD) according to the manufacturer’s instructions, as we
have previously described.39 RNA quality was assessed
using the Agilent Technologies Bioanalyzer on the RNA
Nanochip. RNA-sequencing libraries were prepared using
the TruSeq Stranded Small RNA Kit (Illumina) according
to manufacturer instructions. Samples were indexed in
batches of 48, with a targeted sequencing depth of 10 mil-
lion reads per sample. Sequencing was performed using
50 base pair, single-end reads, using an Illumina NextSeq
500 instrument. Fastq files were trimmed to remove
adapter sequences using Cutadapt version 1.2.146 and
were aligned using Bowtie version 1.0.047 to the following
transcriptome databases: miRBase22 (miRNAs), a subset
of RefSeq v90 (snoRNAs), and custom-modified piRBase
~ 
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v2 (piRNA). Quantification was performed via SamTools48
python implementation, using a custom-built bioin-
formatics architecture (Human Alignment Toolchain,
HATCH, Quadrant Biosciences). To allow for efficient and
meaningful alignment and quantification of RNAs from
the piRBase v2 database, highly similar piRNA sequences
were reduced using a hierarchical clustering approach
and the resulting sequences were termed “wiRNAs.”
The aligned reads were quantile normalized and each
ncRNA feature was scaled (mean-centered and divided by
the feature standard deviation). The normalized ncRNA
profiles for each sample were screened for sphericity using
a principal component analysis prior to statistical analysis
(Figure S2).
2.7 Statistical analysis
First, the training set (n = 430; mTBI = 201 and con-
trols = 229) was used to identify ncRNA candidates for
mTBI diagnosis. For each class of ncRNAs (ie, miRNAs,
wiRNAs, and snoRNAs), a nonparametric Wilcoxon rank
test with Bonferroni correction was used to identity fea-
tures with significant differences between mTBI and con-
trol groups (false detection rate [FDR]< .05).Next, a partial
least squares discriminant analysis (PLSDA) was used to
visualize the ability of each ncRNA class to separate mTBI
and control samples in two dimensions. Variable impor-
tance in projection was calculated for each ncRNA fea-
ture using the weighted sum of absolute regression coeffi-
cients. Then, a random forest analysiswas performed (1000
trees and 10 features) to estimate the out-of-bounds error
for each class of ncRNAs. Mean decrease in accuracy was
estimated for each ncRNA feature. Finally, the top 10 fea-
tures within each ncRNA class onWilcoxon (Adj. P-value),
PLSDA (weighted coefficient sum), and Random Forest
(mean decrease in accuracy) were pooled into a panel of
ncRNA candidates with mTBI diagnostic potential. Dupli-
cate featureswere removed from the candidate list. In total,
65 ncRNA candidates were iteratively assessed for diag-
nostic accuracy in the training set. Accuracy, defined by
area under the receiver operating characteristic curve, was
determined for both individual ncRNA features and ratios
of features. To control for the potential effects of previous
mTBI, sex, race, age, and underlying neuropsychological
comorbidities (eg, anxiety, depression, chronic headache
disorder, and ADHD) on ncRNA levels, these measures
were scaled, log transformed, and incorporated as ratios
with each ncRNA candidate. Missing values (1.8 % of all
measures) were imputed with the singular value decom-
position imputation method. Random forest was used to
generate mTBI-predictive models from sets of individual
ncRNAs and ncRNA ratios. To avoid over-modeling, and to
produce a panel that could be rapidly assessed with qPCR
in downstream applications, no more than 10 ncRNA fea-
tures were allowed in each model. Area under the curve
(AUC) in the training set was assessed with a 100-fold
Monte-Carlo cross validation procedure: two thirds of the
training set samples were used to evaluate feature impor-
tance and build a regression model for cross-validation in
the remaining one third of training set samples. Themodel
with the highest AUC was chosen for external validation.
Coefficients and features in the model were held constant
and applied to the naïve test set (n = 108; mTBI = 50 and
controls = 58). Sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV), and AUC
were reported for both sets.
In the subset of training set participants assessed for
post-concussion symptoms, balance, neurocognition, and
salivary ncRNA (n = 321; mTBI = 176 and control = 145),
random forest was used to generate three models pre-
dicting mTBI status: (a) validated symptom scales (symp-
tom severity and symptom burden on PCSS), (b) perfor-
mance on four neurocognitive tasks, and (c) balance per-
formance in eight stances. Age was included in each pre-
dictive model to control for its potential impacts on neu-
rocognitive and balance performance, as well as symptom
reporting. Model accuracy was assessed across the entire
subset (n = 321) using 100-fold cross-validated (CV) AUC,
as above. To mirror current clinical guidelines, a predic-
tivemodel combining standardized symptom scores on the
PCSS with neurocognitive measures was generated, and
compared to combinedmodels of PCSSwith ncRNA levels,
and PCSS with balance scores. Finally, to assess the max-
imum diagnostic accuracy yielded by combining all four
approaches, random forest was used to generate a model
combining PCSS scores, neurocognitive performance, bal-
ance, and ncRNA levels. To explore potential biases within
each predictive model, medical and demographic features
were compared between misclassified and correctly clas-
sified participants with a two-tailed student’s t test. Selec-
tion of ncRNA features and predictive model generation
was performedwithMetaboanalyst v4.0 online software.49
A post hoc analysis using Power Analysis and Sample
Size Software (PASS version 15.0.4; NCSS, LLC, Kaysville,
UT) determined that the sample size used in the training
set provided >99% power to detect a difference between
the null AUC (AUC = .70, indicative of acceptable clin-
ical utility) and the alternative hypothesis (AUC = .85,
estimated from our previously published research).37 A
one-sided z-test was used with an alpha level set at .05
for continuous data with equal variances and binomial
outcomes. The validation cohort achieved 87.6% power to
differentiate the ncRNA model performance (AUC = .83)
from the null hypothesis value (AUC = .70).
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2.8 Physiologic relevance
To assess the physiologic relevance of the ncRNA fea-
tures that were predictive of mTBI status, we used a three-
step approach. First, we assessed whether ncRNA lev-
els trended back toward control levels over time, using
679 longitudinal samples collected from the mTBI partici-
pants. Nonparametric ANOVA was used to assess levels of
the nine ncRNAs used in the diagnostic algorithm across
five time points: <72 h (n = 129), 4-7 days (n = 120), 8-14
days (n = 190), 15-30 days (n = 105), and 31-60 days postin-
jury (n= 135). One sample per participant was used in each
time point. Second, relationships between the nine ncR-
NAs of interest and individual symptoms (reported subjec-
tively on the PCSS and measured objectively through neu-
rocognitive and balance testing) were assessed with a Pear-
son correlation analysis. Third, high confidence gene tar-
gets (Targetscan Context Score < –0.5, P-value < .01) for
the miRNAs of interest were identified in DIANA miR-
PATH v3.0 online software.50 Overrepresentation of Kyoto
Encyclopedia of Genes andGenomes (KEGG) pathways by
these target genes was determined using a Fishers Exact
Test with Bonferroni correction. For snoRNAs of inter-
est, chromosome location, base pair size, orthologues, and
proximal protein-coding genes were provided using NCBI
Entrez Gene. Diseases associated with the proximal gene
were identified in Genecards.
3 RESULTS
3.1 Participant characteristics
On average, participants were 18 (±6) years of age (Table 1).
The majority (331/538, 61%) were male and White race
(335/538, 61%). Therewas no significant difference (P> .05)
between themTBI group and the control group in age, sex,
or race for both the training and test sets. Self-reported
rates of anxiety (24/538, 4%), depression (20/538, 4%),
ADHD (36/538, 7%), and chronic headache (25/538, 5%)
were low. There were no significant differences between
groups in anxiety or ADHD in both training and test sets.
The mTBI group had higher rates of chronic headache
in the training set (P = .022) and higher rates of depres-
sion in the test set (P = .029). Factors that could poten-
tially impact saliva ncRNA content, such as average time
of saliva collection (14:00± 4:00 h), mean bodymass index
(24 ± 7 kg/m2), rates of dietary restrictions (38/538, 7%),
and recent exercise (77/538, 14%) did not differ significantly
among mTBI and control groups in either the training or
test set. The two groups had similar rates of prior lifetime
concussions (141/538, 26%). There were 45 participants in
the control group with OI (15%), and 20 sustained head
impacts during exercise (mean hits-to-head = 8; range =
1-50).
3.2 Characteristics of mTBIs and
related symptoms
On average, mTBI participants were enrolled 4 (± 4) days
postinjury. The most common mechanism of injury was
sport-related (185/251, 74%), with football (59/251, 32%) and
soccer (39/185, 21%) being the most common (Table 2).
Falls (33/251, 13%), motor vehicle accidents (9/251, 4%),
and “other” injury mechanisms (24/251, 10%) accounted
for the remainder of mTBIs. Among mTBI participants, 73
of 251 (29%) reported retro- or antero-grade memory loss,
and 40 of 251 (16%) reported loss of consciousness imme-
diately following the injury. There were 33 participants
(16%) that reported postconcussive symptoms at 4 weeks
beyond the time of injury. The most commonly reported
symptoms among mTBI participants at the time of enroll-
ment were “headache” (166/251, 66%), “don’t feel right”
(144/251, 57%), “pressure in head” (141/251, 56%), “diffi-
culty concentrating” (136/251, 54%), and “fatigue” (134/251,
53%). ThemTBI participants endorsed significantly greater
severity (FDR < .05; 7-point Likert scale) for each of the
22 symptoms when compared with control participants.
Total symptom severity (sum of Likert scores for 22 symp-
toms) was also greater in the mTBI group (29± 26) than in
the control group (4 ± 9; P < .001). The number of symp-
toms among mTBI participants (11/22 symptoms, ±7) was
greater than for control participants (2/22 symptoms, ± 4;
P < .001).
3.3 Balance and neurocognitive
assessment
Balance and cognitive testing were completed in a subset
of mTBI (n = 179) and control (n = 147) participants using
the ClearEdge Toolkit (Table S1). Themagnitude of the dif-
ference between the groups was dependent on which bal-
ance and cognitive test was administered. ThemTBI group
displayed significantly (P < .05) greater body sway during
TLEO (d = 0.57), TLEC (d = 0.53), TSEO (d = 0.46), TSEC
(d = 0.48), and TLEOFP (d = 0.45) tasks compared with
the control group. There were no significant differences
(P> .05) in body sway between the two groups on TLECFP,
TSEOFP, and TSECFP tasks. The mTBI group displayed
significantly (P < .05) lower scores on all four neurocogni-
tive assessments, including SRT1 (d = 1.1), SRT2 (d = 1.1),
PRT (d = 0.97), and GNG (d = 1.1) testing.











TABLE 1 Participant medical and demographic characteristics
All participants (n = 538) Train set mTBI (n = 201) Train set CTRL (n = 239) P-value Test set mTBI (n = 50) Test set CTRL (n = 58)
COUNT AVG/PCT SD COUNT AVG/PCT SD COUNT AVG/PCT SD COUNT AVG/PCT SD COUNT AVG/PCT SD P-value
Demographics
Age (years) 0 18.3 5.8 0 17.9 7.3 18.9 3.9 .09 0 17.1 7.1 18.4 4.16 .28
Sex (%M) 331 0.61 114 0.57 150 0.64 .05 29 0.58 38 0.66 .43
Race (White) 335 0.62 99 0.49 172 0.74 .74 26 0.52 38 0.66 .5
Race (Black) 48 0.09 11 0.05 25 0.11 .46 3 0.06 9 0.16 .29
Race (Asian) 6 0.01 1 0 5 0.02 .32 0 0 0 0 NA
Hispanic 22 0.04 4 0.02 13 0.06 .78 2 0.04 3 0.05 .66
Medical characteristics
Anxiety 24 0.04 6 0.03 14 0.06 .14 1 0.02 3 0.05 .39
Depression 20 0.04 6 0.03 10 0.04 .47 4 0.08 0 0 .03
Chronic
headache
25 0.05 17 0.08 4 0.02 .02 4 0.08 0 0 .08
ADHD 36 0.07 10 0.05 19 0.08 .19 4 0.08 3 0.05 .55








24.4 7.5 24.9 10.6 24 4.2 .23 23.8 5.9 24.9 5.7 .37
Dietary
restrictions
38 0.07 14 0.07 17 0.07 .93 1 0.02 6 0.1 .09
Recent
exercise




141 0.26 59 0.29 58 0.25 .24 12 0.24 12 0.21 .59
Orthopedic
injury
































Days postinjury 4.3 3.5 4.3 3.57 4 3.3
Injury mechanism
Sport 185 0.74 144 0.72 41 0.82
MVC 9 0.04 9 0.04 0 0
Fall 33 0.13 30 0.15 3 0.06





73 0.56 61 0.3 12 0.24
Loss of
consciousness
at time of injury




37 0.15 33 0.16 4 0.08
Postconcussion symptom scale
Headache 158 1.4 1.8 166 2.4 1.8 20 0.2 0.7 2.6 × 10–41 130 2.3 1.8 15 0.2 0.8 1.2 × 10–30 36 2.7 1.6 5 0.2 0.4 6.2 × 10–13
Pressure in head 91 1.0 1.5 141 1.6 1.6 17 0.2 0.7 1.3E × 10–25 113 1.7 1.6 8 0.1 0.6 2.2 × 10–22 28 1.5 1.4 9 0.4 0.8 1.4 × 10–4
Neck pain 66 0.6 1.3 77 0.9 1.4 14 0.2 0.6 3.3 × 10–10 66 1.0 1.6 10 0.1 0.6 1.9 × 10–9 11 0.6 1.1 4 0.2 0.6 6.4 × 10–2
Nausea or
vomiting
119 0.4 1.1 62 0.7 1.3 4 0.0 0.3 9.2 × 10–11 51 0.8 1.4 2 0.0 0.3 2.5 × 10–9 11 0.7 1.3 2 0.1 0.4 1.2 × 10–2
Dizziness 86 0.8 1.5 109 1.4 1.7 10 0.1 0.6 7.0 × 10–18 82 1.3 1.7 4 0.1 0.7 5.2 × 10–13 27 1.8 1.7 6 0.2 0.4 8.0 × 10–7
Blurred vision 107 0.5 1.2 78 0.8 1.3 8 0.1 0.6 5.1 × 10–10 60 0.8 1.4 7 0.1 0.7 1.7 × 10–7 18 0.9 1.4 1 0.0 0.2 4.8 × 10–4
Balance problems 147 0.6 1.1 90 0.9 1.2 17 0.1 0.5 7.6 × 10–13 72 0.9 1.3 13 0.1 0.5 4.3 × 10–10 18 1.0 1.3 4 0.1 0.3 4.4 × 10–4



































154 0.9 1.5 113 1.4 1.6 10 0.1 0.7 4.1 × 10–20 89 1.4 1.6 9 0.2 0.8 1.5 × 10–14 24 1.8 1.8 1 0.0 0.2 3.0 × 10–7
Feeling slowed
down
116 1.0 1.5 132 1.6 1.6 22 0.2 0.5 9.3 × 10–24 111 1.6 1.7 15 0.2 0.5 1.2 × 10–20 21 1.4 1.5 7 0.3 0.6 1.9 × 10–4
Feeling like in a
fog
162 0.7 1.4 104 1.3 1.6 12 0.1 0.4 2.1 × 10–18 84 1.3 1.7 9 0.1 0.4 1.1 × 10–14 20 1.5 1.8 3 0.1 0.3 5.0 × 10–5
Don’t feel right 173 1.14 1.7 144 2.0 1.9 18 0.2 0.7 6.1 × 10–28 116 1.9 1.9 13 0.2 0.7 2.3 × 10–21 28 2.2 1.9 5 0.2 0.4 3.8 × 10–8
Difficulty
concentrating
131 1.2 1.6 136 1.8 1.8 37 0.4 0.9 4.9 × 10–19 107 1.8 1.8 28 0.4 0.9 1.8 × 10–15 29 2.0 1.8 9 0.5 1.0 6.4 × 10–5
Difficulty
remembering
174 0.8 1.4 110 1.3 1.5 21 0.2 0.7 5.0 × 10–15 90 1.3 1.5 17 0.2 0.7 5.7 × 10–13 20 1.3 1.7 4 0.3 0.9 2.0 × 10–3
Fatigue or low
energy
96 1.2 1.7 134 1.8 1.9 40 0.4 0.9 7.2 × 10–18 110 1.9 1.9 30 0.4 0.9 1.4 × 10–15 24 1.7 1.8 10 0.5 1.0 1.4 × 10–3
Confusion 140 0.6 1.3 88 1.0 1.5 8 0.1 0.5 6.4 × 10–14 70 1.0 1.5 7 0.1 0.5 7.0 × 10–11 18 1.2 1.7 1 0.0 0.2 2.4 × 10–4
Drowsiness 86 1.0 1.6 118 1.6 1.8 22 0.2 0.7 2.6 × 10–19 96 1.6 1.8 17 0.2 0.7 1.7 × 10–15 22 1.8 2.0 5 0.2 0.6 3.8 × 10–5
More emotional 103 0.6 1.2 74 0.9 1.4 12 0.1 0.5 3.0 × 10–10 60 0.9 1.5 8 0.1 0.4 2.8 × 10–9 14 1.0 1.6 4 0.3 0.8 2.4 × 10–2
Irritability 63 0.7 1.4 82 1.1 1.6 21 0.2 0.6 2.6 × 10–10 65 1.0 1.7 17 0.2 0.5 1.2 × 10–8 17 1.2 1.6 4 0.3 0.9 6.6 × 10–3
Sadness 113 0.4 1.0 49 0.6 1.2 14 0.1 0.5 2.0 × 10–5 41 0.6 1.3 11 0.1 0.6 9.5 × 10–5 8 0.4 1.0 3 0.1 0.3 8.8 × 10–2
Nervous or
anxious
115 0.7 1.3 81 0.9 1.4 32 0.4 0.9 1.0 × 10–5 66 0.9 1.5 25 0.4 1.0 9.1 × 10–5 15 0.9 1.4 7 0.4 0.8 4.5 × 10–2
Trouble falling
asleep
284 0.7 1.4 74 1.0 1.6 41 0.4 0.9 1.3 × 10–4 63 1.1 1.7 30 0.4 0.9 7.5 × 10–5 11 0.7 1.3 11 0.6 1.0 7.0 × 10–1
Symptom burden 7.1 7.0 11.0 6.9 2.4 3.9 8.9 × 10–42 10.9 6.7 2.2 3.8 4.7 × 10–34 11.6 6.1 3.2 4.0 3.4 × 10–9
Symptom severity 17.5 23.4 28.8 25.5 4.1 9.1 1.1 × 10–28 28.5 26.3 4.0 9.6 2.8 × 10–22 30.4 22.9 4.9 6.8 3.9E-08
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F IGURE 1 Noncoding RNAs with the largest differences between mTBI and control participants. The hierarchically clustered heatmaps
display the 10 miRNAs (A), snoRNAs (B), and wiRNAs (C) with the largest differences between mTBI (n = 201) and control participants
(n = 229) in the training set on Wilcoxon testing. Saliva levels of each noncoding RNA feature are denoted with red (high expression) or blue
(low expression). Color scales indicate quantile-normalized expression levels
3.4 Salivary RNA assessment
Among the 538 saliva samples assessed with high-
throughput RNA sequencing, the mean quality score was
34.6 (±0.4; range: 32.1-35.1) and the average read count
was 6.9 × 107 (±4.1 × 107; range: 7.9 × 106 to 2.5 × 108).
After filtering out ncRNA features with <10 raw read
counts in >90% of samples, there were 264 miRNAs, 4603
wiRNAs, and 176 Refseq RNAs (including lncRNAs and
snoRNAs) remaining. The most common features in each
ncRNA class were miR-27b-3p (present in 100%, mean raw
read count: 32 619), RNA5-8SN3 (present in 100% of sam-
ples, mean raw read count: 11 334), and wiRNA_2 (present
in 100% of samples, mean raw read count: 538 703).
There were 28 miRNAs, 21 Refseq RNAs, and 1378
wiRNAs with significant (FDR < .05) differences between
mTBI and control groups on Wilcoxon testing (Table S2).
There were 16 of 28 (57%) miRNAs, 12 of 21 (57%) Refseq
RNAs, and 675 of 1378 (49%) wiRNAs upregulated in the
mTBI group. The 10 ncRNA features in each class with
the most significant between-group differences are dis-
played in Figure 1A–C. Separate two-dimensional PLSDAs
employing each class of ncRNA were used to visualize
their ability to differentiate mTBI and control groups.
No class of ncRNAs was able to achieve full separation
of mTBI and control groups on PLSDA (Figure S3A-C).
Coefficient scores estimating the importance of each
individual ncRNA feature in sample projection were used
to identify the top 10 RNA candidates within each category
(Table S2). Random forest, employing 1000 trees and 10
features, was used to estimate the error rate for each class
of ncRNAs for determining mTBI status (Figure S4A-C).
The 10 features within each ncRNA category that provided
the largest mean decrease in accuracy on random forest
were identified (Table S2). Finally, the top 10 ncRNAs
within each category (miRNA, Refseq RNA, and wiRNA)
from Wilcoxon, PLSDA, and random forest analyses were
concatenated into a list of candidate features for mTBI
diagnosis (Table 3). After removing duplicate features,
there were 65 ncRNA features, including 22 miRNAs, 17
RefSeq RNAs, and 26 wiRNAs remaining.
3.5 Diagnostic utility
A predictive model utilizing seven ratios, involving nine
ncRNAs along with participant age and chronic headache
status, differentiated mTBI and control participants with
CV AUC of .857 (95% CI, .816-.903) in the training set and
an AUC of .823 in the test set (Figure 2A). The model
correctly identified 190 of 251 (76%) mTBI participants
and 232 of 287 (81%) control participants (PPV = 81%;
NPV = 76%). In the subset of participants with symptom,
neurocognitive, and balance data (n = 321), a model
employing total number of symptoms and total symptom
severity on the PCSS, along with participant age, was able
to differentiate mTBI and control participants with CV
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F IGURE 2 Diagnostic accuracy of saliva noncoding RNA, symptom scales, neurocognitive testing, and balance assessment for mTBI. A
receiver operating characteristic (ROC) curve is displayed for a predictive model using seven ratios of nine non-coding RNAs (ncRNAs) plus
participant age and chronic headache history to differentiate individuals with mTBI from peers (A). Accuracy, determined by cross-validated
area under the curve (CV-AUC), is shown for both training (blue; n= 430) and test sets (pink; n= 108). In a subset of participants (n= 321), cross-
validated accuracy of models employing symptom burden and symptom severity plus participant age (B), neurocognitive performance plus
participant age (C), or balance performance plus participant age (D)were assessed. The combined predictive utility of symptomburden/severity
and performance on four neurocognitive tests (E) was compared with symptom burden/severity and four saliva noncoding RNAs (F), symptom
burden/severity and eight balance measures (G), and a model combining symptoms, neurocognition, balance, and saliva RNAs (H). Shaded
areas denote the 95% confidence interval for CV-AUC
correctly identified 136 of 176 (77%) mTBI participants
and 129 of 145 (89%) control participants (PPV = 89%;
NPV = 76%). A model employing four neurocognitive
measures along with participant age differentiated mTBI
and control participants with CV AUC of .835 (95% CI,
.782-.880; Figure 2C). The model correctly identified 124 of
176 (70%) mTBI participants and 126 of 145 (87%) control
participants (PPV= 87%; NPV= 75%). A model employing
eight balance measures along with participant age differ-
entiated mTBI and control participants with CV AUC of
.853 (95% CI, .803-.899; Figure 2D). The model correctly
identified 126 of 176 (72%) mTBI participants and 127 of 145
(88%) control participants (PPV = 88%; NPV = 76%). Per
clinical guidelines for mTBI assessment,16 we examined
the combined ability of validated symptom scales and
computerized neurocognitive testing to identify mTBI
within our cohort. A predictive model employing symp-
tom severity, symptom burden, performance on four
neurocognitive measures, and age differentiated mTBI
and control participants with CV AUC of .888 (95% CI,
.845-.925; Figure 2E). The model correctly identified 142 of
175 (81%) mTBI participants and 131 of 145 (90%) control
participants (PPV = 90%; NPV= 81%). In comparison, a
model combining symptom severity and symptom burden
with levels of four ncRNAs and participant age differenti-
ated mTBI and control participants with CV AUC of .932
(95% CI, .890-.965; Figure 2F). The model correctly identi-
fied 146 of 176 (83%) mTBI participants and 129 of 145 (89%)
control participants (PPV = 89%; NPV = 83%). A model
combining symptom severity and symptom burden with
eight balance tests and participant age differentiatedmTBI
and control participants with CV AUC of .912 (95% CI,
.868-.952; Figure 2G). The model correctly identified 140 of
176 (80%) mTBI participants and 128 of 145 (88%) control
participants (PPV = 88%; NPV = 80%). Finally, a model
combining all features (symptom severity, symptom bur-
den, levels of four ncRNAs, performance on eight balance
tests, and four neurocognitive tests, along with participant
age) differentiated mTBI and control participants with CV
AUC of .925 (95% CI, .880-.960; Figure 2H). The model cor-
rectly identified 143 of 176 (81%) mTBI participants and 133
of 145 (92%) control participants (PPV = 92%; NPV = 81%).
Components of each model can be found in Table S3.
3.6 Misclassification analysis
A two-tailed student’s t-test was used to compare charac-
teristics of correctly and incorrectly classified participants
and identify potential biases within eachmodel (Table S4).
ncRNA Model Symptom Model Neurocog Model Balance Model 
,...;; CV-AUC: .857 CV-AUC: .885 CV-AUC: .835 CV-AUC: .853 
2 
95 % CI: (.836 - .918) 95 % CI: (.836 - .9 I 8) 95 % CI: (.803 - .899) "' 95 % CI: (.782 - .880) ~ 




Symptom+ Neurocog Symptom + ncRNA Symptom + Balance Combined Model 
CV-AUC: .888 CV-AUC: .932 CV-AUC: .912 CV-AUC: .925 
95 % CI: (.845 - .925) 95 % CI: (.890 - .965) 95 % CI: (.868 - .952) 95 % CI: (.880 - .960) 
I - Specificity (False Positive Rate) 
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The ncRNA model was more likely (P < .05) to correctly
classify participants with a history of previous concussion
(P = .045), anxiety (P = .041), White race (P = .017), or
OI (controls only, P = .037). Incorrect classification was
more likely for participants with higher symptom severity
(P= .0093), particularly those with high levels of headache
symptoms (P = .014). However, the ncRNA model dis-
played no difference (P > .05) in classification accuracy
for participants with other commonly reported symptoms,
including “balance problems,” “fatigue,” or “difficulty
concentrating.” The 37 mTBI participants who reported
persistent symptoms 30 days postinjury were classified
with similar accuracy as mTBI participants with symptom
resolution by day 30 (P = .80). There was no difference
between correctly and incorrectly classified participants
in mTBI status, recent exercise, time since injury (mTBI
group only), sex, age, body mass index, depression, or
ADHD. For the model based on validated symptom scores,
correct classification was more frequent than misclassi-
fication for participants with recent exercise (P = .015),
history of previous concussion (P = .045), White race
(P = .0025), and prolonged symptoms (P = .037). Incorrect
classification was more likely for participants with mTBI
(P = .00020), younger participants (P = .0019), and par-
ticipants with ADHD (P = .047). There were no signif-
icant differences (P > .05) between correctly and incor-
rectly classified participants with respect to time since
injury (mTBI group), body mass index, anxiety, or depres-
sion. The model combining ncRNA and validated symp-
tom scores displayed no difference between correctly and
incorrectly classified participants in mTBI status, recent
exercise, time since injury (mTBI group), sex, history of
previous concussion, bodymass index, anxiety, depression,
orADHD.Correct classificationwasmore likely for partici-
pantswith younger age (P= .0079),White race (P= .0004),
and prolonged symptoms (P = .039). The model was more
accurate for participants reporting high levels of headache
(P= .0003), balance problems (P= .013), difficulty concen-
trating (P = .0003), or fatigue (P = .0007), as well as those
with higher symptom burden (P= .0013).Misclassification
characteristics for balance and neurocognitive models are
also displayed in Table S4.
3.7 Longitudinal trends for miRNAs
that predict mTBI status
Nonparametric ANOVA was used to assess if the ncR-
NAs used to predict mTBI status displayed longitudinal
trends toward a “control baseline” level in the 60 days
postinjury. There was a significant difference (P < .05)
in levels of four of five miRNAs across the four time
points (Figure 3A). Only one of five snoRNAs dis-
played significant differences across the four time points
(Figure 3B).
3.8 Relationships between ncRNAs and
mTBI symptoms
A Pearson correlation analysis was used to identify
significant (FDR < .01) relationships between ncRNAs
used in the predictive algorithm and mTBI symptoms
(measured by PCSS, neurocognitive testing, and bal-
ance assessment) for 321 individuals. There were three
ncRNAs associated with symptom severity (miR-4510:
R = –.22 and FDR = 3.4 × 10–6; SNORD57: R = .19 and
FDR = 5.3 × 10–4; SNORD104: R = .13 and FDR = .008).
Levels of miR-4510 were most strongly associated with
severity of “Headache,” whereas levels of SNORD104 and
SNORD57 were most strongly associated with “Dizziness”
(Figure 4). There were no ncRNAs from the predictive
algorithm that were associated with performance scores
' CLINICAL AND TRANSLATIONAL MEDICINE ~-
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F IGURE 3 Longitudinal expression of diagnostic noncoding RNAs following mTBI. The heatmaps display salivary levels of five micro-
ribonucleic acids (miRNAs; A) and five small nucleolar RNAs (snoRNAs; B) used in the noncoding RNA (ncRNA) predictive model or the
combined symptom/ncRNA model. Levels of each ncRNA are displayed for control participants (CTRL; N = 287) at enrollment, as well as
mTBI participants (N = 251) sampled across 0-3 days (n = 129), 4-7 days (n = 120), 8-14 days (n = 190), 15-30 days (n = 105), and 30-60 days
(n = 135) postinjury. For each ncRNA, differences across postinjury time points were assessed with nonparametric analysis of variance (χ2 and
P-values shown). Hierarchical clustering demonstrates relationships between individual ncRNA features. Blue denotes low expression and red
denotes high expression. Color scales indicate quantile-normalized expression levels
on neurocognitive or balance testing (Figure S6A
and S6B).
3.9 Physiologic relevance of predictive
ncRNAs
The putative gene targets for the four miRNAs used in
the predictive algorithm (miR-34a-5p, miR-4510, miR-
27a-5p, and miR-192-5p) were interrogated in DIANA
miRPath v3 (Table 4). These four miRNAs demonstrated
259 high confidence messenger RNA targets, overrep-
resenting four physiologic pathways: synaptic vesicle
cycle (FDR = 3.0 × 10–5, four genes, and two miRNAs),
GABAergic synapse (FDR = .0026, three genes, and two
miRNAs), transforming growth factor-beta signaling path-
way (FDR = .0026, four genes, and three miRNAs), and
SNARE interactions in vesicular transport (FDR = .0056,
four genes, and two miRNAs). The five snoRNAs used
in the predictive algorithm arose from five separate
chromosomes, and ranged from 60 to 75 base pairs in
length. Protein coding genes proximal to these snoRNAs
mTBI Pval 
A 8-14 days 15-30 days 30-60 days 
hsa-miR-1246 28.7 9.0E-6 
hsa-miR-192-5p 7.9 0.09 
hsa-miR-4510 10.0 0.04 
hsa-miR-34a-5p 17.2 0.002 
hsa-miR-27a-5p 22.6 0.0001 
)(2 Pval 
B 
SNORD2 1.1 0.7 
SNORD75 1.3 0.7 
SNORD59A 7.9 0.04 
SNORD57 0.4 0.9 
SNORD104 0.1 0.9 
~ 
~ 
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were implicated in several neurologic conditions, includ-
ing Wernicke-Korsakoff Syndrome (Tex2/SNORD104),
Spinocerebellar Ataxia (Nop56/SNORD57), and Parkinson
Disease (EIF4A2/SNORD2; Table S5).
4 DISCUSSION
This study identifies a set of ncRNA biomarkers in saliva
that differentiate individuals with mTBI from peers with-
out mTBI in both training (n = 430) and naive test sets
(n= 108). In a subset of participants assessed with comput-
erized neurocognitive testing, objective balance measures,
and standardized symptom scales (n = 321), the ncRNA
model displays similar accuracy for identifying mTBI sta-
tus as these more traditional approaches.16 Importantly,
the ncRNA model was not biased by recent exercise, time
since injury (mTBI group), sex, history of previous con-
cussion, bodymass index, or underlying neuropsychologic
conditions.
A model combining levels of four ncRNAs with
subjective symptom reports yields comparable accuracy
(AUC = .932) to that achieved with symptom reports and
four neurocognitive measures (AUC = .888), or symptom
reports and eight balance measures (AUC= .912). We note
that none of these algorithms received the benefit of clin-
ical acumen and injury history, which may explain why
their diagnostic accuracy lags published rates.51 Unfor-
tunately, the development of mTBI biomarkers depends
upon comparison to subjective assessments on which the
original mTBI diagnosis is based. This “circular compar-
ison” can make it difficult to determine the true accu-
racy of any emerging technology. Here, we use a control
group consisting of individuals with anxiety, depression,
ADHD, OI, and exercise-related fatigue to mimic many of
the functional symptoms observed after mTBI. Although
the majority of these control participants reported no
mTBI symptoms, their mean symptom severity score (4)
likely increased misclassification rates for mTBI partici-
pantswith symptoms severity scores between one and four.
Current clinical guidelines recommend that healthcare
providers use age-appropriate symptom scales with or
without computerized neurocognitive testing to diagnose
mTBI, and specifically suggest that blood biomarkers only
be used in research settings.16 The present results indi-
cate that saliva ncRNA biomarkers yield similar diag-
nostic accuracy to a limited neurocognitive battery and
provide additive value when combined with an algo-
rithm relying solely on symptom scores (unaided by injury
history). However, adding neurocognitive measures to a
symptom/ncRNAmodel hadminimal impact on accuracy.
Thus, the additional time required to administer and inter-
pret neurocognitive tests may not provide added bene-
fit when combined with saliva ncRNA testing. This may
be because neurocognitive testing and subjective symp-
tom reports capture parallel information (ie, fatigue, con-
centration, and memory), whereas ncRNA may represent
a more direct measure of biologic changes with additive
value. Because biological changes do not provide informa-
tion about the clinical manifestation of mTBI, it is crucial
that suchmeasures be used only as an adjunct to symptom
reports and functional assessments.
In the present study, ncRNAs were measured with RNA
sequencing technology, which requires >24 h to return
results. However, we have previously shown that ncR-
NAs measured with a multiplex assay (≤4 h) yield com-
parable results.39 Emerging technology may soon pro-
vide the ability to measure ncRNAs field-side using a
portable device within 1 h.52–54 Until that time, bal-
ance and neurocognitive testing remain more expedient
adjuncts. However, these assessments usually require an
experienced healthcare provider, and many youth or high
school competitions/practices do not have an experienced
provider present. In comparison,minimalmedical training
is required to collect a saliva sample using the nucleic acid
stabilizing kits employed here. Collection is completed
in 10 s (without gagging the patient), samples are stabile
at room temperature (for up to 3 months), and they can
be transported to a lab without the biohazard regulations
required for blood. Unlike neurocognitive testing, saliva
ncRNA levels cannot be manipulated by individuals seek-
ing to delay/expedite return to work or school.17–19
The scientific principle underlying our approach is that
ncRNAs are packaged into vesicles and released into saliva
by cranial nerves.34 The ncRNA content of salivary vesi-
cles may change in order to regulate neuroinflamma-
tion and synaptic repair following mTBI. Indeed, func-
tional analysis of the four miRNAs within the mTBI pre-
dictive model displays enrichment for genes involved in
the synaptic vesicle cycle, SNARE interactions in vesic-
ular transport, and GABAergic synapse. Numerous stud-
ies in animal models have identified alterations in GABA
signaling networks following TBI,55,56 and GABA imbal-
ances have been implicated in specific symptomology
following injury.57,58 Transforming growth factor-beta is
also implicated as a physiologic mechanism underlying
mTBI,59,60 and the candidate ncRNAs target this pathway
as well.
To our knowledge, this study is approximately five times
larger than any previous study of ncRNA expression in
mTBI.33 Additional strengths include the use of train-
ing and naïve test sets to validate the ncRNA diagnostic
algorithm, and the recruitment of a control group with
comparable age, sex, ethnicity, neuropsychologic history,
and rates of previous concussion. Inclusion of individuals
with recent exercise, OI, and subconcussive head impacts
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within the control group serves to increase the scientific
rigor. Recruitment of participants from 11 different sites
and multiple clinic settings (ie, ED, sports medicine clin-
ics, urgent care, and outpatient primary care clinics) also
promotes generalizability. Finally, direct comparison to
current standard-of-care assessments provides initial evi-
dence for the clinical utility of ncRNA biomarkers.
There are, however, several limitations to this study.
No baseline cognitive or symptom data were available
for participants, despite that fact that baseline testing is
known to improve the accuracy of these measures.61,62
Similarly, baseline levels of ncRNAs were not obtained,
though reverse baseline measurements suggest preinjury
saliva testing might also improve the accuracy of this
technique. Although we attempted to match numerous
medical and demographic characteristics across mTBI
and control participants, complete matching was not
possible for all categories, and rates of chronic headache
disorder differed across groups. In addition, rates of
neuropsychologic comorbidities (ie, ADHD, anxiety, and
depression) are slightly lower in this cohort than in the
general population,63 which may affect generalizability
of the findings. Although the ncRNA predictive model
was built and validated in a cohort of 538 individuals,
only 321 of these individuals completed a full battery
of neurocognitive, balance, and symptom assessments.
Some participants (63/538; 12%) were unable/unwilling
to complete the full battery of tests, some sites (3/11)
could not administer the full battery within their clinic
workflow, and individuals with primary language other
than English were excluded because the neurocognitive
battery required English fluency. Thus, this subcohort may
include an element of selection bias. This also highlights
some of the shortcomings involved with time-consuming
functional measures. We note that identification of mTBI
participants in this study was reliant on physical and
cognitive symptom assessments. Thus, the ncRNAs
identified here may not improve sensitivity for mTBI
identification. Future studies assessing ncRNA levels
among asymptomatic individuals immediately following
head impacts could determine if these molecules have the
ability to increase diagnostic sensitivity.
Of the four miRNAs used in our ncRNA predictive algo-
rithm, three (miR-34a-5p, miR-192-5p, and miR-27a-5p)
were identified in previous studies of miRNA expression
in individuals with TBI.38,62,64,65 One miRNA (miR-4510)
has not been identified previously, and to our knowledge
no previous mTBI study has interrogated snoRNAs or
wiRNAs. Differences between our findings and existing
literature may arise because of differences in (a) severity
of brain injury; (b) participant age; (c) RNA quantification
methodology; (d) sample sizes; and (e) biofluids. Even our
own pilot studies of miRNA expression used an expecto-
ration technique (rather than swab) to collect saliva, and
involved younger participants.37
In conclusion, this study demonstrates that saliva
ncRNA levels may be used as an objectivemeasure to iden-
tifymTBI status in concert with currently available clinical
tools. In the present cohort, this biologic measure has sim-
ilar diagnostic accuracy to neurocognitive or balance test-
ing, and displays additive value with standardized symp-
tom assessment. External validation of this ncRNA model
would provide additional evidence that biomarker testing
deserves further consideration within clinical guidelines
for mTBI diagnosis. Prognostic application of this technol-
ogy may provide even greater clinical benefit—nearly 25%
of individualswithmTBI suffer fromprolonged symptoms,
yet few accurate tools exist to predict the course of recov-
ery. Given that saliva ncRNA measurement is objective,
noninvasive, and does not require expert administration
or interpretation, such ameasure could represent a signifi-
cant advance in standard of care for individualswithmTBI.
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